Geode Capital Management
KLDO

Geode Capital Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Geode Capital Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-336,879
Closed -$555K – 5087
2022
Q1 		$555K Sell
336,879
-1,541
-0.5% -$2.75K ﹤0.01% 3884
2021
Q4 		$808K Sell
338,420
-36,181
-10% -$147K ﹤0.01% 3810
2021
Q3 		$2.04M Buy
374,601
+35,296
+10% +$219K ﹤0.01% 3342
2021
Q2 		$2.52M Buy
339,305
+72,001
+27% +$510K ﹤0.01% 3193
2021
Q1 		$2.17M Buy
267,304
+57,452
+27% +$626K ﹤0.01% 3221
2020
Q4 		$1.91M Buy
209,852
+38,220
+22% +$314K ﹤0.01% 3112
2020
Q3 		$1.9M Buy
171,632
+33,772
+24% +$234K ﹤0.01% 2896
2020
Q2 		$1.02M Buy
137,860
+6,631
+5% +$44.4K ﹤0.01% 3128
2020
Q1 		$807K Buy
131,229
+19,371
+17% +$126K ﹤0.01% 3097
2019
Q4 		$561K Buy
111,858
+33,937
+44% +$216K ﹤0.01% 3462
2019
Q3 		$586K Buy
77,921
+103
+0.1% +$894 ﹤0.01% 3414
2019
Q2 		$902K Buy
+77,818
New +$1.13M ﹤0.01% 3265

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Geode Capital Management's KLDO Position: Q2 2022 in Review

Geode Capital Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 336,879 shares — an estimated $555K sold.

Geode Capital Management first reported a position in KLDO in Q2 2019 and held it in 12 quarters. The position peaked at $2.52M in Q2 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Geode Capital Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Geode Capital Management sold 336,879 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $555K.
  • Geode Capital Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Geode Capital Management's Kaleido Biosciences, Inc. Common Stock position peaked at $2.52M in Q2 2021.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Geode Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.